KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) Research & Development (2017 - 2025)

Historic Research & Development for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $4.5 million.

  • Co-Diagnostics' Research & Development fell 818.88% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year decrease of 1568.73%. This contributed to the annual value of $21.0 million for FY2024, which is 863.58% down from last year.
  • Co-Diagnostics' Research & Development amounted to $4.5 million in Q3 2025, which was down 818.88% from $4.7 million recorded in Q2 2025.
  • Co-Diagnostics' Research & Development's 5-year high stood at $6.2 million during Q4 2023, with a 5-year trough of $2.2 million in Q4 2021.
  • Over the past 5 years, Co-Diagnostics' median Research & Development value was $4.9 million (recorded in 2025), while the average stood at $4.8 million.
  • Per our database at Business Quant, Co-Diagnostics' Research & Development skyrocketed by 53926.89% in 2021 and then tumbled by 2220.2% in 2024.
  • Co-Diagnostics' Research & Development (Quarter) stood at $2.2 million in 2021, then surged by 117.17% to $4.7 million in 2022, then skyrocketed by 30.37% to $6.2 million in 2023, then fell by 22.2% to $4.8 million in 2024, then dropped by 6.79% to $4.5 million in 2025.
  • Its Research & Development was $4.5 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.9 million in Q1 2025.